LNC Therapeutics, the biotechnology company specialized in biomedical research and development based on the workings of the intestinal microbiome is consolidating its foothold in Bordeaux with the creation of a research platform.
The new structure will supplement the regulatory and clinical teams of LNC Therapeutics and will host scientists specialized in microbiology, cellular and molecular biology.
A new structure hosted by the campus laboratories
Founded in Bordeaux in 2010, the company
develops new medication to fight against wide-impact diseases such as obesity
and metabolic disorders, the historical therapeutic fields of the company.
After 7 years of research, LNC Therapeutics reached a milestone in 2018 with a successful move into the biotech world and the launch of microbiome projects.
LNC now hopes to expand its expertise to other diseases for which the medical needs are not being met.
‘With the creation of this new research platform, LNC Therapeutics now possesses all the necessary tools to roll out its strategy to become one of the leaders in intestinal microbiome.’ says Georges Rawadi, Managing Director of LNC Therapeutics.
Funded essentially by venture capital (€1.6m raised since its creation), the company chose Bordeaux over Paris to open its R&D department in the Biomedical Innovation Technological Platform (PTIB) located in the Bordeaux Inno Campus technology park in Pessac.
Attached to Bordeaux University and Xavier Arnozan hospital, the aim of the PTIB is to promote research in the field of biotechnologies and healthcare.
Located in the heart of the university hospital campus, LNC Therapeutics thus benefits from close contacts with diverse teams in the fields of academic and clinical research, proximity to patients and access to state-of-the-art technology.
A favorable and vibrant ecosystem
‘Bordeaux is a favorable and vibrant ecosystem for LNC, with willing partners to develop innovative projects, solid regional support programs for innovation and high value-added training, in addition to being a great city to live in!’ explains Georges Rawadi, Managing Director of LNC Therapeutics.
By the end of 2019, LNC Therapeutics will employ 15 people (scientific profiles mainly from the pharmacy and biotech fields) and hopes to reach around 30 employees within 3 years.
Invest in Bordeaux supported LNC Therapeutics’ expansion in Bordeaux with the search for premises to accommodate the research platform and by building contacts with relevant local structures.
‘As LNC recruits international profiles, Invest in Bordeaux is also an excellent information relay for candidates’.
Contact: Caroline Bernard – Corporate Communication & Investor Relations Manager